Alternative Treatments for eBC and mBC


Key opinion leaders (KOLs) discuss the use of CDK4/6 inhibitors in early breast cancer, specifically in patients who have undergone chemotherapy and surgery. They highlight the key factors that help determine which patients are most likely to benefit from receiving these medications.

Video content above is prompted by the following questions:

  • Which phase of treatment is abemaciclib appropriate in?
    • What are the patient characteristics that must be present in order to utilize abemaciclib?
    • Do these criteria influence your treatment decisions in patients with early breast cancer?
  • What is the study design and methods of the NATALEE trial and what have the results demonstrated so far?
Related Videos
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
A panel of 4 experts on breast cancer
A panel of 4 experts
A panel of 4 experts
Video 12 - "Empowering RSV Patients: Essential Vaccine Education Resources"
Video 11 - "Unmet Needs in Prevention and Management of RSV"
Video 9 - "Unmet Needs in Relapsed or Refractory Multiple Myeloma"
© 2024 MJH Life Sciences

All rights reserved.